• 0Shopping Cart
AmideBio LLC
  • ABOUT
  • TEAM
    • Management and Operations
    • Board of Directors
    • Advisory Board
  • SCIENCE
    • Therapeutic Pipeline
    • Discovery
    • Manufacturing
  • PRODUCTS
    • Amyloid Peptides
    • Amyloid Kits and Buffers
    • Bowman-Birk Inhibitors
    • Brazzeins
    • Proinsulin
    • Toxins and Knottins
    • Custom Product Inquiry
    • Request Quote
  • NEWS
  • SUPPORT
    • CONTACT
    • Frequently Asked Questions
    • Application Notes
    • Inquiry Form
  • My Account
    • Checkout
    • Login
  • Search
  • Menu
Blog - Latest News
You are here: Home / Privacy Policy / 2018_5_AmideBio Press Release Pawel Fludzinski CEO

2018_5_AmideBio Press Release Pawel Fludzinski CEO

2018-05-15/by Admino

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.amidebio.com/wp-content/uploads/2016/07/ABlogo3-300x138.gif 0 0 Admino https://www.amidebio.com/wp-content/uploads/2016/07/ABlogo3-300x138.gif Admino2018-05-15 14:36:452018-05-15 14:36:452018_5_AmideBio Press Release Pawel Fludzinski CEO

COMPANY NEWS

  • AMIDEBIO Granted Rare Pediatric Disease Designation by FDA for Novel Solution Stable Glucagon2020-08-20 - 07:40
  • AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon2020-04-22 - 17:35
  • AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33
  • David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47
  • Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio2018-09-03 - 22:37
Scroll to top